DK2780011T3 - Kombinationsterapi mod ovariecancer - Google Patents
Kombinationsterapi mod ovariecancer Download PDFInfo
- Publication number
- DK2780011T3 DK2780011T3 DK12783804.3T DK12783804T DK2780011T3 DK 2780011 T3 DK2780011 T3 DK 2780011T3 DK 12783804 T DK12783804 T DK 12783804T DK 2780011 T3 DK2780011 T3 DK 2780011T3
- Authority
- DK
- Denmark
- Prior art keywords
- gemcitabine
- pyridin
- imidazo
- imidazol
- ylamine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (9)
1. 5-[2-tert-butyl-5-(4-fluor-phenyl)-1 H-imidazol-4-yl]-3-(2,2-dimethyl-propyl)-3H-imidazo[4,5-b]pyridin-2-ylamin eller et farmaceutisk acceptabelt salt deraf til anvendelse i kombination med gemcitabin og et platinmiddel udvalgt blandt cisplatin og carboplatin ved behandling af ovariecancer.
2. 5-[2-tert-butyl-5-(4-fluor-phenyl)-1 H-imidazol-4-yl]-3-(2,2-dimethyl-propyl)-3H-imidazo[4,5-b]pyridin-2-ylamin eller et farmaceutisk acceptabelt salt deraf til anvendelse ifølge krav 1, hvor indgivelse af 5-[2-tert-butyl-5-(4-fluor-phenyl)-1 H-imidazol-4-yl]-3-(2,2-dimethyl-propyl)-3H-imidazo[4,5-b]pyridin-2-ylamin eller et farmaceutisk acceptabelt salt deraf kommer før indgivelse af gemcitabin og platinmidlet.
3. 5-[2-tert-butyl-5-(4-fluor-phenyl)-1 H-imidazol-4-yl]-3-(2,2-dimethyl-propyl)-3H-imidazo[4,5-b]pyridin-2-ylamin eller et farmaceutisk acceptabelt salt deraf til anvendelse ifølge krav 1 eller 2, hvor gemcitabin og platinmidlet indgives op til 2 dage efter indgivelse af 5-[2-tert-butyl-5-(4-fluor-phenyl)-1 H-imidazol-4-yl]-3-(2,2-dimethyl-propyl)-3H-imidazo[4,5-b]pyridin-2-ylamin eller et farmaceutisk acceptabelt salt deraf, og gemcitabin indgives igen op til 7 dage senere.
4.
5-[2-tert-butyl-5-(4-fluor-phenyl)-1 H-imidazol-4-yl]-3-(2,2-dimethyl-propyl)-3H-imidazo[4,5-b]pyridin-2-ylamin eller et farmaceutisk acceptabelt salt deraf til anvendelse ifølge krav 1, hvor indgivelse af gemcitabin og platinmidlet kommer før indgivelse af 5-[2-tert-butyl-5-(4-fluor-phenyl)-1 H-imidazol-4-yl]-3-(2,2-dimethylpropyl)-3H-imidazo[4,5-b]pyridin-2-ylamin eller et farmaceutisk acceptabelt salt deraf. 5. 5-[2-tert-butyl-5-(4-fluor-phenyl)-1 H-imidazol-4-yl]-3-(2,2-dimethyl-propyl)-3H-imidazo[4,5-b]pyridin-2-ylamin eller et farmaceutisk acceptabelt salt deraf til anvendelse ifølge krav 1-2, hvor gemcitabin og platinmidlet indgives samtidigt.
6. 5-[2-tert-butyl-5-(4-fluor-phenyl)-1 H-imidazol-4-yl]-3-(2,2-dimethyl-propyl)-3H-imidazo[4,5-b]pyridin-2-ylamin eller et farmaceutisk acceptabelt salt deraf til anvendelse ifølge et hvilket som helst af kravene 1-5, hvor platinmidlet er cisplatin.
7. 5-[2-tert-butyl-5-(4-fluor-phenyl)-1 H-imidazol-4-yl]-3-(2,2-dimethyl-propyl)-3H-imidazo[4,5-b]pyridin-2-ylamin eller et farmaceutisk acceptabelt salt deraf til anvendelse ifølge et hvilket som helst af kravene 1-5, hvor platinmidlet er carboplatin.
8. 5-[2-tert-butyl-5-(4-fluor-phenyl)-1 H-imidazol-4-yl]-3-(2,2-dimethyl-propyl)-3H-imidazo[4,5-b]pyridin-2-ylamin eller et farmaceutisk acceptabelt salt deraf til anvendelse ifølge et hvilket som helst af kravene 1-7 i en 21-dages behandlingscyklus.
9. 5-[2-tert-butyl-5-(4-fluor-phenyl)-1 H-imidazol-4-yl]-3-(2,2-dimethyl-propyl)-3H-imidazo[4,5-b]pyridin-2-ylamin eller et farmaceutisk acceptabelt salt deraf til anvendelse ifølge et hvilket som helst af kravene 1-8, hvor det farmaceutisk acceptable salt er dimethansulfonatsalt.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161558582P | 2011-11-11 | 2011-11-11 | |
| PCT/US2012/062634 WO2013070460A1 (en) | 2011-11-11 | 2012-10-31 | Combination therapy for ovarian cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2780011T3 true DK2780011T3 (da) | 2018-05-28 |
Family
ID=47146746
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK12783804.3T DK2780011T3 (da) | 2011-11-11 | 2012-10-31 | Kombinationsterapi mod ovariecancer |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US9844529B2 (da) |
| EP (1) | EP2780011B1 (da) |
| JP (1) | JP6055481B2 (da) |
| KR (1) | KR101647569B1 (da) |
| CN (1) | CN103917233B (da) |
| AP (1) | AP3881A (da) |
| AU (1) | AU2012336154B2 (da) |
| BR (1) | BR112014011197A2 (da) |
| CA (1) | CA2850559C (da) |
| CR (1) | CR20140211A (da) |
| CY (1) | CY1120315T1 (da) |
| DK (1) | DK2780011T3 (da) |
| DO (1) | DOP2014000100A (da) |
| EA (1) | EA026297B1 (da) |
| ES (1) | ES2671730T3 (da) |
| HR (1) | HRP20180875T1 (da) |
| HU (1) | HUE037928T2 (da) |
| IL (1) | IL232479A0 (da) |
| LT (1) | LT2780011T (da) |
| ME (1) | ME03035B (da) |
| MX (1) | MX2014005698A (da) |
| MY (1) | MY168927A (da) |
| PL (1) | PL2780011T3 (da) |
| PT (1) | PT2780011T (da) |
| RS (1) | RS57256B1 (da) |
| SG (1) | SG11201401795XA (da) |
| SI (1) | SI2780011T1 (da) |
| TN (1) | TN2014000150A1 (da) |
| WO (1) | WO2013070460A1 (da) |
| ZA (1) | ZA201403159B (da) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3125920B1 (en) | 2014-04-04 | 2020-12-23 | Del Mar Pharmaceuticals | Dianhydrogalactitol, diacetyldianhydrogalactitol or dibromodulcitol to treat non-small-cell carcinoma of the lung and ovarian cancer |
| CN114732910A (zh) | 2017-10-05 | 2022-07-12 | 弗尔康医疗公司 | P38激酶抑制剂降低dux4和下游基因表达以用于治疗fshd |
| US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000038519A1 (en) | 1998-12-31 | 2000-07-06 | Sugen, Inc. | 3-heteroarylidenyl-2-indolinone compounds for modulating protein kinase activity and for use in cancer chemotherapy |
| TWI332003B (en) | 2004-01-30 | 2010-10-21 | Lilly Co Eli | Kinase inhibitors |
-
2012
- 2012-10-31 PT PT127838043T patent/PT2780011T/pt unknown
- 2012-10-31 MX MX2014005698A patent/MX2014005698A/es unknown
- 2012-10-31 BR BR112014011197A patent/BR112014011197A2/pt not_active IP Right Cessation
- 2012-10-31 DK DK12783804.3T patent/DK2780011T3/da active
- 2012-10-31 HU HUE12783804A patent/HUE037928T2/hu unknown
- 2012-10-31 LT LTEP12783804.3T patent/LT2780011T/lt unknown
- 2012-10-31 CA CA2850559A patent/CA2850559C/en not_active Expired - Fee Related
- 2012-10-31 MY MYPI2014701157A patent/MY168927A/en unknown
- 2012-10-31 SI SI201231285T patent/SI2780011T1/en unknown
- 2012-10-31 ME MEP-2018-132A patent/ME03035B/me unknown
- 2012-10-31 EA EA201490766A patent/EA026297B1/ru not_active IP Right Cessation
- 2012-10-31 KR KR1020147012229A patent/KR101647569B1/ko active IP Right Grant
- 2012-10-31 PL PL12783804T patent/PL2780011T3/pl unknown
- 2012-10-31 ES ES12783804.3T patent/ES2671730T3/es active Active
- 2012-10-31 AP AP2014007631A patent/AP3881A/en active
- 2012-10-31 US US14/354,244 patent/US9844529B2/en not_active Expired - Fee Related
- 2012-10-31 EP EP12783804.3A patent/EP2780011B1/en active Active
- 2012-10-31 WO PCT/US2012/062634 patent/WO2013070460A1/en active Application Filing
- 2012-10-31 JP JP2014541100A patent/JP6055481B2/ja not_active Expired - Fee Related
- 2012-10-31 SG SG11201401795XA patent/SG11201401795XA/en unknown
- 2012-10-31 AU AU2012336154A patent/AU2012336154B2/en not_active Ceased
- 2012-10-31 RS RS20180602A patent/RS57256B1/sr unknown
- 2012-10-31 CN CN201280054290.7A patent/CN103917233B/zh not_active Expired - Fee Related
-
2014
- 2014-04-10 TN TNP2014000150A patent/TN2014000150A1/en unknown
- 2014-04-30 ZA ZA2014/03159A patent/ZA201403159B/en unknown
- 2014-05-05 IL IL232479A patent/IL232479A0/en unknown
- 2014-05-09 CR CR20140211A patent/CR20140211A/es unknown
- 2014-05-09 DO DO2014000100A patent/DOP2014000100A/es unknown
-
2018
- 2018-06-05 HR HRP20180875TT patent/HRP20180875T1/hr unknown
- 2018-06-08 CY CY20181100601T patent/CY1120315T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7146016B2 (ja) | Ｓｈｐ２の活性を阻害するための化合物および組成物 | |
| JP6862404B2 (ja) | 骨髄異形成症候群を治療するためのタンパク質ホスファターゼ２ａ阻害剤 | |
| EP3868764A1 (en) | Sting-agonist compound | |
| TW202323253A (zh) | 四氫-吡啶并[3,4-b]吲哚雌激素受體調節劑及其用途 | |
| JPWO2008111441A1 (ja) | 医薬組成物 | |
| EP2906564B1 (en) | Treating brain cancer using agelastatin a (aa) and analogues thereof | |
| JP2022541330A (ja) | Ｓｔｉｎｇアゴニストとしての大環状化合物並びにその方法及び使用 | |
| EP3911417B1 (en) | Heterocyclic nlrp3 modulators , for use in the treatment of cancer | |
| DK2780011T3 (da) | Kombinationsterapi mod ovariecancer | |
| WO2021016333A1 (en) | Aryl sulfonamides as small molecule stat3 inhibitors | |
| CA3233554A1 (en) | Combination therapy using a ptpn11 inhibitor and a kras g12c inhibitor | |
| JPWO2019039525A1 (ja) | Ａｘｌ阻害剤を有効成分として含むがん治療剤 | |
| CA3213359A1 (en) | Alk-5 inhibitors and uses thereof | |
| NZ623622B2 (en) | Combination therapy for ovarian cancer | |
| WO2024112397A1 (en) | Combination therapies comprising kras inhibitors and sph2 inhibitors | |
| JP2022023033A (ja) | ガンの処置に有用なｔｉｅ２キナーゼの阻害方法 | |
| WO2023205794A1 (en) | Combination therapy using a pyrimidone derivative as ptpn11 inhibitor and a pd-1/pd-l1 inhibitor and its use in the treatment of cancer | |
| WO2023174314A1 (zh) | 氮杂环丁烷衍生物的用途及治疗方法 |